Literature DB >> 3281020

Development of amphotericin B liposomes bearing antibody specific to Candida albicans.

D R Hospenthal1, A L Rogers, G L Mills.   

Abstract

Liposomes expressing external antibody specific for Candida albicans and encapsulating amphotericin B were developed and characterized in this study. Antibody was first modified by the covalent attachment of palmitic acid residues. Liposomes were produced by reverse-phase evaporation and modified antibody was incorporated into these liposomes via the hydrophobic interaction between the palmitic acid and the phospholipids composing the liposomes. The liposomes were characterized as to the amount of amphotericin B by spectroscopy and for the presence of antibody by protein analysis and secondary immunolabeling by fluorescent and electron microscopic methods. Immunogold labeling showed that the antibody was being expressed externally on the liposomes in the electron microscopic studies and the specificity of these liposomes for C. albicans was observed by secondary immunofluorescence.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281020     DOI: 10.1007/bf00455667

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  16 in total

1.  Causes of death in patients with malignant lymphoma.

Authors:  R Feld; G P Bodey; V Rodriguez; M Luna
Journal:  Am J Med Sci       Date:  1974-08       Impact factor: 2.378

2.  An improved method for covalent attachment of antibody to liposomes.

Authors:  D F Shen; A Huang; L Huang
Journal:  Biochim Biophys Acta       Date:  1982-07-14

3.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

5.  Use of esters of N-hydroxysuccinimide in the synthesis of N-acylamino acids.

Authors:  Y Lapidot; S Rappoport; Y Wolman
Journal:  J Lipid Res       Date:  1967-03       Impact factor: 5.922

6.  Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R L Hopfer; R Mehta; K Mehta; E M Hersh; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

8.  Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice.

Authors:  G Lopez-Berestein; R L Hopfer; R Mehta; K Mehta; E M Hersh; R L Juliano
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

9.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination.

Authors:  R T Mehta; G Lopez-Berestein; R L Hopfer; K Mehta; R A White; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more
  9 in total

1.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  The development and application of ultrastructural research in mycology.

Authors:  K L Klomparens
Journal:  Mycopathologia       Date:  1990-02       Impact factor: 2.574

Review 3.  Amphotericin B: delivery systems.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 4.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

Review 5.  New antifungal agents for the systemic mycoses.

Authors:  S M Ringel
Journal:  Mycopathologia       Date:  1990-02       Impact factor: 2.574

6.  Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B.

Authors:  T Belay; D R Hospenthal; A L Rogers; M J Patterson
Journal:  Mycopathologia       Date:  1993-07       Impact factor: 2.574

7.  Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis.

Authors:  D R Hospenthal; A L Rogers; E S Beneke
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 8.  Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.

Authors:  Francelise B Cavassin; João Luiz Baú-Carneiro; Rogério R Vilas-Boas; Flávio Queiroz-Telles
Journal:  Infect Dis Ther       Date:  2021-02-01

Review 9.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.